Intrauterine adhesions
Conditions
Interventions
experimental group: kunning oral solution
control group:placebo
Sponsors
Beijing Friendship Hospital, Capital Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Subjects must meet all of the following criteria to be selected: (1) It meets the diagnostic criteria of western medicine for intrauterine adhesions, and it belongs to mild or moderate intrauterine adhesions; (2) In line with the TCM syndrome differentiation, the diagnostic criteria of qi stagnation and blood stasis syndrome; (3) Female patients >= 18 years old and <= 45 years old; (4) Intrauterine adhesions occurred after intrauterine surgery, and hysteroscopic intrauterine adhesions separation was needed; (5) Volunteer to participate in clinical trials and sign informed consent.
Exclusion criteria
Exclusion criteria: Subjects meeting one or more of the following criteria will be excluded: (1) Physiological amenorrhea, such as pregnancy or lactation, or less menstruation and amenorrhea caused by hyperprolactinemia, polycystic ovary syndrome, premature ovarian failure, pituitary disease or thyroid disease; (2) Those who plan to become pregnant within the last 3 months; (3) Patients with other endometrial diseases (such as fibroids, tuberculosis, uterine malformation, endometriosis, etc.) confirmed by hysteroscopy; (4) Patients with acute and subacute genital tract inflammation; (5) Complicated with other diseases, such as breast disease, thrombosis prone disease, lung disease, etc.; (6) Patients with severe hypertension, cardiovascular, cerebrovascular, liver, kidney, hematopoietic system and other serious primary diseases; (7) ALT and AST of liver function exceed 1.5 times of the upper limit of reference value, or SCR of kidney function exceed the upper limit of reference value; (8) Patients who had undergone intrauterine adhesion separation; (9) Patients with mental or neurological diseases; (10) Patients with malignant tumor disease; (11) Patients treated with estrogen or progesterone one month before surgery; (12) People with allergic constitution, allergy or intolerance to known ingredients or any excipients of the drug studied; (13) Suspecting or having a history of alcohol and drug abuse; (14) Participating in or currently participating in other clinical trials within the last 3 months; (15) The researchers consider it inappropriate to conduct clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Menstruation score;Markers of endometrial receptivity;TCM syndrome scoring;Endometrial thickness under ultrasound;Endometrium and subendometrium blood flow parameters under ultrasound;Endometrial typing;Hysteroscopic evaluation of uterine cavity morphology; | — |
Countries
China
Contacts
Public ContactShi Wang
Outcome results
None listed